title: [State of the liver antioxidant system and content of matrix metalloproteinase-2 of the large intestine under the effect of maleimide derivative in experimental colorectal carcinogenesis in rats].
abstract: The maleimide derivative--1-(4-Cl-benzyl)-3-Cl-4-(CF3-phenylamino)-1H-pyrrol-2.5-dione (MI-1) with cytostatic activity did not cause substantial changes of liver antioxidant system and level of matrix metalloproteinase-2 in intestinal mucosa after chronic treatment (for 20 weeks). MI-1 did not cause significant changes in the content of thiobarbituric-active products and plasma membrane protein carbonyl groups in the rat liver. However activities of superoxide dismutase, glutathione peroxidase, and content of reduced glutathione were decreased in both doses--0.027 and 2.7 mg/kg. The level of matrix metalloproteinase-2 in intestinal mucosa was decreased just in maximum dose--2.7 mg/kg. The contents of thiobarbituric-active products, protein carbonyl groups, reduced glutathione, matrix metalloproteinase-2, activities of glutathione peroxidase and glutathione-S-transferase in the liver cells have increased in 1.2-dimethylhydrazine-induced colon cancer in rats. The activities of enzymes of the first line of antioxidant defense--superoxide dismutase and catalase were decreased to 40%. The maleimide derivative prevents development of oxidation stress and partially reduce them to control level.
authors.forename: O M
authors.initials: OM
authors.lastname: Filins'ka
authors.forename: S V
authors.initials: SV
authors.lastname: Iablons'ka
authors.forename: S Ia
authors.initials: SIa
authors.lastname: Mandryk
authors.forename: I V
authors.initials: IV
authors.lastname: Kharchuk
authors.forename: H V
authors.initials: HV
authors.lastname: Ostrovs'ka
authors.forename: V K
authors.initials: VK
authors.lastname: Rybal'chenko
mesh_terms: D019813:1,2-Dimethylhydrazine; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000975:Antioxidants / Q000378:metabolism*; D015153:Blotting, Western; D002374:Catalase / Q000378:metabolism; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005979:Glutathione Peroxidase / Q000378:metabolism; D005982:Glutathione Transferase / Q000378:metabolism; D007413:Intestinal Mucosa / Q000187:drug effects / Q000201:enzymology; D007420:Intestine, Large / Q000187:drug effects / Q000201:enzymology*; D008099:Liver / Q000187:drug effects / Q000201:enzymology* / Q000378:metabolism; D008297:Male; D008301:Maleimides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D020778:Matrix Metalloproteinase 2; D061965:Matrix Metalloproteinase Inhibitors; D015394:Molecular Structure; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D013482:Superoxide Dismutase / Q000378:metabolism; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism
chemical_list: C550019:1-(4-Cl-benzyl)-3-Cl-4-(CF3-phenylamino)-1H-pyrrol-2.5-dione; D000970:Antineoplastic Agents; D000975:Antioxidants; D008301:Maleimides; D061965:Matrix Metalloproteinase Inhibitors; D017392:Thiobarbituric Acid Reactive Substances; D002374:Catalase; D005979:Glutathione Peroxidase; D013482:Superoxide Dismutase; D005982:Glutathione Transferase; D020778:Matrix Metalloproteinase 2; C522363:Mmp2 protein, rat; D019813:1,2-Dimethylhydrazine